The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance–linked ATP binding cassette drug transporter ABCG2

Vitamin K3 (menadione; 2-methyl-1,4-naphthoquinone) is a structural precursor of vitamins K1 and K2, which are essential for blood clotting. The naturally occurring structural analogue of this vitamin, plumbagin (5-hydroxy-menadione), is known to modulate cellular proliferation, apoptosis, carcinogenesis, and radioresistance. We here report that both vitamin K3 and plumbagin are substrates of the multidrug resistance–linked ATP binding cassette drug transporter, ABCG2. Vitamin K3 and plumbagin specifically inhibited the ABCG2-mediated efflux of mitoxantrone but did not have any effect on the ABCB1-mediated efflux of rhodamine 123. This inhibition of ABCG2 function was due to their interaction at the substrate-binding site(s). Vitamin K3 and plumbagin inhibited the binding of [125I]iodoarylazidoprazosin, a substrate of ABCG2, to this transporter in a concentration-dependent manner with IC50 values of 7.3 and 22.6 μmol/L, respectively, but had no effect on the binding of the photoaffinity analogue to ABCB1. Both compounds stimulated ABCG2-mediated ATP hydrolysis and also inhibited the mitoxantrone-stimulated ATPase activity of the ABCG2 transporter, but did not have any significant effect on the ATPase activity of ABCB1. In a cytotoxicity assay, ABCG2-expressing HEK cells were 2.8- and 2.3-fold resistant to plumbagin and vitamin K3, respectively, compared with the control cells, suggesting that they are substrates of this transporter. Collectively, these data show for the first time that vitamin K3 is a substrate of the ABCG2 transporter. Thus, ABCG2 may have a role in the regulation of vitamin K3 levels in the body. In addition, vitamin K3 and its structural derivative, plumbagin, could potentially be used to modulate ABCG2 function. [Mol Cancer Ther 2007;6(12):3279–86]

[1]  P. U. Devi,et al.  Modification of bone marrow radiosensensitivity by medicinal plant extracts. , 1997, The British journal of radiology.

[2]  C. Dinney,et al.  Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. , 2006, The Journal of urology.

[3]  J. Saunders,et al.  Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro. , 1997, Anti-cancer drugs.

[4]  J. Verrax,et al.  Oxidative stress by ascorbate/menadione association kills K562 human chronic myelogenous leukaemia cells and inhibits its tumour growth in nude mice. , 2006, Biochemical pharmacology.

[5]  S. Ambudkar.  Drug-stimulatable ATPase activity in crude membranes of human MDR1-transfected mammalian cells. , 1998, Methods in enzymology.

[6]  Devi Pu,et al.  EFFECT OF PLUMBAGIN ON THE RADIATION INDUCED CYTOGENETIC AND CELL CYCLE CHANGES IN MOUSE EHRLICH ASCITES CARCINOMA IN VIVO , 1998 .

[7]  T. Litman,et al.  Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  R. A. Flath,et al.  Eight 1,4-naphthoquinones from Juglans , 1989 .

[9]  M. Dolan,et al.  Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. , 1998, Anti-cancer drugs.

[10]  H. Rosing,et al.  Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B2) into Milk , 2006, Molecular and Cellular Biology.

[11]  T. Tsuruo,et al.  MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  W. Schaffner,et al.  A rapid, sensitive, and specific method for the determination of protein in dilute solution. , 1973, Analytical biochemistry.

[13]  B. Aggarwal,et al.  Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Suppresses NF-κB Activation and NF-κB-regulated Gene Products Through Modulation of p65 and IκBα Kinase Activation, Leading to Potentiation of Apoptosis Induced by Cytokine and Chemotherapeutic Agents* , 2006, Journal of Biological Chemistry.

[14]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[15]  C. Vergely,et al.  In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. , 1993, Cancer research.

[16]  N. Udupa,et al.  Niosomal Plumbagin with Reduced Toxicity and Improved Anticancer Activity in BALB/C Mice , 1996, The Journal of pharmacy and pharmacology.

[17]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Bates,et al.  Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity , 2003, British Journal of Cancer.

[19]  P. U. Devi,et al.  Effect of plumbagin on the radiation induced cytogenetic and cell cycle changes in mouse Ehrlich ascites carcinoma in vivo. , 1998, Indian journal of experimental biology.

[20]  G. Szakács,et al.  Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. , 2006, Physiological reviews.

[21]  J. Verrax,et al.  Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death , 2004, Apoptosis.

[22]  M Dietel,et al.  Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. , 1999, Journal of the National Cancer Institute.

[23]  P. Kuo,et al.  Plumbagin (5-Hydroxy-2-methyl-1,4-naphthoquinone) Induces Apoptosis and Cell Cycle Arrest in A549 Cells through p53 Accumulation via c-Jun NH2-Terminal Kinase-Mediated Phosphorylation at Serine 15 in Vitro and in Vivo , 2006, Journal of Pharmacology and Experimental Therapeutics.

[24]  A. Cheng,et al.  Menadione: spectrum of anticancer activity and effects on nucleotide metabolism in human neoplastic cell lines. , 1991, Biochemical pharmacology.

[25]  I. Pastan,et al.  Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. , 1986, Science.

[26]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.

[27]  S. Ambudkar,et al.  Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. , 2004, Biochemical pharmacology.

[28]  Z. Sauna,et al.  Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  T. Litman,et al.  A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). , 2001, Biochimica et biophysica acta.

[30]  Suneet Shukla,et al.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. , 2006, Biochemistry.

[31]  P Bevan,et al.  Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  J. Suttie,et al.  Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements. , 1997, Pediatrics.

[33]  J. Doroshow,et al.  Phase I study of mitomycin C and menadione in advanced solid tumors , 1995, Cancer Chemotherapy and Pharmacology.

[34]  N. Udupa,et al.  Reduced toxicity and enhanced antitumor efficacy of betacyclodextrin plumbagin inclusion complex in mice bearing Ehrlich ascites carcinoma. , 1997, Indian journal of physiology and pharmacology.

[35]  T. S. Srivastava,et al.  Circumvention of adriamycin resistance: effect of 2-methyl-1,4-naphthoquinone (vitamin K3) on drug cytotoxicity in sensitive and MDR P388 leukemia cells. , 1992, Cancer letters.

[36]  J. Doroshow,et al.  Mitomycin C and menadione for the treatment of lung cancer: a phase II trial , 2004, Investigational New Drugs.

[37]  P. Kuo,et al.  Plumbagin induces G2-M arrest and autophagy by inhibiting the AKT/mammalian target of rapamycin pathway in breast cancer cells , 2006, Molecular Cancer Therapeutics.

[38]  C. Wu,et al.  Binary/ternary combined effects of vitamin K3 with other antitumor agents in nasopharyngeal carcinoma CG1 cells. , 2000, International journal of oncology.

[39]  Z. Sauna,et al.  The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). , 2004, Molecular pharmacology.

[40]  T. Dale,et al.  The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk , 2005, Nature Medicine.

[41]  T. Terao,et al.  Vitamin K prophylaxis to prevent neonatal vitamin K deficient intracranial haemorrhage in Shizuoka prefecture , 1996, British journal of obstetrics and gynaecology.

[42]  H. Yoshiji,et al.  Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. , 2005, International journal of oncology.

[43]  Vincenzo,et al.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.

[44]  T. Fojo,et al.  Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.